These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 17596848

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Bicalutamide demonstrates biologic effectiveness in prostate cancer cell lines and tumor primary cultures irrespective of Her2/neu expression levels.
    Gravina GL, Festuccia C, Millimaggi D, Tombolini V, Dolo V, Vicentini C, Bologna M.
    Urology; 2009 Aug; 74(2):452-7. PubMed ID: 19285710
    [Abstract] [Full Text] [Related]

  • 4. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.
    Gravina GL, Marampon F, Di Staso M, Bonfili P, Vitturini A, Jannini EA, Pestell RG, Tombolini V, Festuccia C.
    Prostate; 2010 Aug; 70(11):1166-78. PubMed ID: 20333699
    [Abstract] [Full Text] [Related]

  • 5. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
    Gravina GL, Festuccia C, Millimaggi D, Dolo V, Tombolini V, de Vito M, Vicentini C, Bologna M.
    Prostate; 2008 May 15; 68(7):793-801. PubMed ID: 18324645
    [Abstract] [Full Text] [Related]

  • 6. Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer.
    Gravina GL, Festuccia C, Galatioto GP, Muzi P, Angelucci A, Ronchi P, Costa AM, Bologna M, Vicentini C.
    Urology; 2007 Oct 15; 70(4):728-33. PubMed ID: 17991545
    [Abstract] [Full Text] [Related]

  • 7. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L, Giocanti N, Hennequin C, Favaudon V.
    Prostate; 2010 Mar 01; 70(4):401-11. PubMed ID: 19902473
    [Abstract] [Full Text] [Related]

  • 8. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ, Dionne CA, Jani J, Angeles T, Murakata C, Lamb J, Isaacs JT.
    Cancer Res; 1999 May 15; 59(10):2395-401. PubMed ID: 10344749
    [Abstract] [Full Text] [Related]

  • 9. Correlations among neural cell adhesion molecule, nerve growth factor, and its receptors, TrkA, TrkB, TrkC, and p75, in perineural invasion by basal cell and cutaneous squamous cell carcinomas.
    Chen-Tsai CP, Colome-Grimmer M, Wagner RF.
    Dermatol Surg; 2004 Jul 15; 30(7):1009-16. PubMed ID: 15209791
    [Abstract] [Full Text] [Related]

  • 10. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma.
    Zhigang Z, Wenlu S.
    Prostate; 2005 Dec 01; 65(4):299-305. PubMed ID: 16015594
    [Abstract] [Full Text] [Related]

  • 11. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
    Yoshida T, Kinoshita H, Segawa T, Nakamura E, Inoue T, Shimizu Y, Kamoto T, Ogawa O.
    Cancer Res; 2005 Nov 01; 65(21):9611-6. PubMed ID: 16266977
    [Abstract] [Full Text] [Related]

  • 12. Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.
    Landriscina M, Bagalà C, Piscazzi A, Schinzari G, Quirino M, Fabiano A, Bianchetti S, Cassano A, Sica G, Barone C.
    Prostate; 2009 May 15; 69(7):744-54. PubMed ID: 19152342
    [Abstract] [Full Text] [Related]

  • 13. Neurotrophin receptor expression in human primary retinoblastomas and retinoblastoma cell lines.
    Stephan H, Zakrzewski JL, Bölöni R, Grasemann C, Lohmann DR, Eggert A.
    Pediatr Blood Cancer; 2008 Feb 15; 50(2):218-22. PubMed ID: 17973327
    [Abstract] [Full Text] [Related]

  • 14. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H, Eide T, Krobert KA, Levy FO, Dizeyi N, Bjartell AS, Abrahamsson PA, Taskén KA.
    Prostate; 2008 Jul 01; 68(10):1133-42. PubMed ID: 18454446
    [Abstract] [Full Text] [Related]

  • 15. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C, Wafa LA, Lamoureux F, Cheng H, Fazli L, Gleave ME, Rennie PS.
    Prostate; 2012 Jun 01; 72(8):875-85. PubMed ID: 22072572
    [Abstract] [Full Text] [Related]

  • 16. Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer.
    Festuccia C, Gravina GL, Muzi P, Pomante R, Ventura L, Vessella RL, Vicentini C, Bologna M.
    Endocr Relat Cancer; 2007 Sep 01; 14(3):601-11. PubMed ID: 17914091
    [Abstract] [Full Text] [Related]

  • 17. p75 and TrkC neurotrophin receptors demonstrate a different immunoreactivity profile in comparison to TrkA and TrkB receptors in human normal pituitary gland and adenomas.
    Assimakopoulou M, Zolota V, Chondrogianni C, Gatzounis G, Varakis J.
    Neuroendocrinology; 2008 Sep 01; 88(2):127-34. PubMed ID: 18319596
    [Abstract] [Full Text] [Related]

  • 18. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
    Boutin B, Tajeddine N, Vandersmissen P, Zanou N, Van Schoor M, Mondin L, Courtoy PJ, Tombal B, Gailly P.
    Prostate; 2013 Jul 01; 73(10):1090-102. PubMed ID: 23532738
    [Abstract] [Full Text] [Related]

  • 19. Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth.
    Peternac D, Klima I, Cecchini MG, Studer UE, Thalmann GN.
    J Urol; 2006 Jul 01; 176(1):354-60. PubMed ID: 16753443
    [Abstract] [Full Text] [Related]

  • 20. Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells.
    Kawabata R, Oie S, Oka T, Takahashi M, Kanayama H, Itoh K.
    Int J Oncol; 2011 Mar 01; 38(3):665-76. PubMed ID: 21243325
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.